LYEL
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. (LYEL) has 13 SEC Form 4 filings (13 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Jul 28, 2026.
Insiders have net bought $25.0M over the trailing 6 months. The largest single insider purchase in this window was $12.5M by 10% Owner ARCH Venture Partners IX, LLC on Mar 6, 2026.
- Industry:Biotechnology
- CEO:Lynn Seely
- Employees:300
- HQ:South San Francisco, CA, US
- IPO:2021-06-17
Insider Buying
$25.0M
reported purchases (SEC code P)
Insider Selling
$41K
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Market Cap
$317.3M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| 10% Owner | Sale | 10 | $137 | Jul 20 | SEC ↗ | |
Innovative Cellular Therapeutics Holdings LtdFirst filing | 10% Owner | Sale | 10 | $137 | Jul 18 | SEC ↗ |
Seely LynnFirst filing | President and CEO | Sale | 388 | $7K | Jun 15 | SEC ↗ |
Lee Gary K.First filing | Chief Scientific Officer | Sale | 130 | $2K | Jun 15 | SEC ↗ |
Hill Stephen J.First filing | Chief Operating Officer | Sale | 89 | $2K | Jun 15 | SEC ↗ |
Bulis Veronica SanchezFirst filing | VP, Corporate Controller | Sale | 217 | $4K | Jun 15 | SEC ↗ |
Shook DavidFirst filing | Chief Medical Officer | Sale | 1,977 | $25K | Jun 11 | SEC ↗ |
ARCH Venture Partners IX, LLCFirst filing | 10% Owner | Purchase | 488,090 | $12.5M | Mar 9 | SEC ↗ |
ARCH Venture Fund XIII, L.P.First filing | 10% Owner | Purchase | 488,090 | $12.5M | Mar 9 | SEC ↗ |
Related companies
Lyell Immunopharma, Inc. is in the Healthcare sector.